NCT04572308View on ClinicalTrials.gov

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

May 30, 2021

Conditions

T-cell Acute Lymphoblastic Leukemia/Lymphoma

Interventions

BIOLOGICAL

CD7 CAR-T

"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"

Trial Locations (1)

Unknown

Hebei yanda Ludaopei Hospital, Yanda

All Listed Sponsors

lead

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

NCT04572308 - Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells | Biotech Hunter | Biotech Hunter